Immune checkpoint inhibitors are tumor immunotherapy drugs that activate the immune system to fight tumor cells by blocking checkpoint receptors, primarily including CTLA-4 and PD-1 or its main ligand PD-L1. The gene discussed is CTLA4; the disease is neoplasm.